EC authorizes Pfizer, BioNTech COVID-19 vaccine

By The Science Advisory Board staff writers

December 23, 2020 -- The European Commission (EC) has granted a conditional marketing authorization to Pfizer and BioNTech for their COVID-19 vaccine.

The vaccine is authorized for use in the European Union (EU) to prevent COVID-19 in individuals 16 years of age and older. The messenger RNA-based vaccine, which received an emergency use authorization in the U.S. in mid-December, is administered in two doses given three weeks apart.

The companies said they can immediately ship initial doses to the 27 member states of the EU. The EC had already entered into an agreement to receive 200 million doses of the vaccine, with an option to buy an additional 100 million doses in 2021.

Pfizer, BioNTech get positive CHMP recommendation for COVID-19 vaccine
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion to recommend the conditional...
Various updates for Pfizer, BioNTech COVID-19 vaccine post-EUA
Various announcements and updates regarding the Pfizer-BioNTech COVID-19 vaccine were made during the weekend and on Monday, December 14. These included...
FDA issues EUA for Pfizer, BioNTech COVID-19 vaccine
The U.S. Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine. The move comes after...
FDA in final stages before issuing Pfizer, BioNTech EUA
The U.S. Food and Drug Administration (FDA) has informed Pfizer and BioNTech that it will work rapidly toward the finalization and issuance of an emergency...
Pfizer, BioNTech's COVID-19 vaccine shows 95% efficacy
In a trial of more than 40,000 participants, Pfizer-BioNTech's COVID-19 vaccine showed a 95% efficacy against the SARS-CoV-2 virus, according to results...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter